Clinical Trial Update: Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LCZ696 (sacubitril/valsartan) versus valsartan in heart failure with preserved ejection fraction; results completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2020-09-29